MacroGenics | MGNX - Selling And Administration Expenses


MacroGenics reported $9.71M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Amgen USD 1.72B 134M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Daiichi Sankyo JPY 249.96B 21.73B Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Genmab DKK 205M 39M Jun/2026
Geron USD 35.42M 6.24M Mar/2026
Gilead Sciences USD 1.52B 70M Jun/2026
J&J USD 6.25B 168M Sep/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Merck USD 2.89B 219M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Xencor USD 77.54M 4.59M Jun/2026